MedAdvisor posts increased loss in ‘pivotal’ year

But medtech company looks to the future as revenue increases significantly ASX-listed medication adherence company MedAdvisor has reported an increased loss after tax for FY22 of close to $17.5 million, an increase on its $14.37 million loss for FY21. But the company also delivered revenue of $67.8 million, a significant 75 per cent increase on

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Research Roundup
Next ‘Fraud’ claims in location stoush